Biomay: Construction Project of Biomay’s Manufacturing Facility Fully on Schedule
14.5.2021 09:01:23 CEST | news aktuell GmbH | Pressemelding
Vienna, Austria - Construction work on Biomay’s new headquarters and biotech manufacturing facility in Aspern Seestadt, Vienna, is progressing on schedule. Seven months after the groundbreaking ceremony in September 2020, the building shell has now been completed. Ongoing activities are currently focused on the interior works and the installation of the complex heat, ventilation and air conditioning (HVAC) and utility systems.
Dr. Hans Huber, Chief Executive Officer of Biomay said: “We are delighted and impressed to witness the rapid and timely progress of our building project. Internal and external engineering teams and the construction workers are doing an excellent job. It is a pleasure to see how all the team members are working together effectively in a concerted effort to meet Biomay’s goals in terms of schedule, quality and budget. Seeing the satisfying progress, we are highly confident that the remaining half of the project will stay on track as well.”
As for the months to come, the building as such is planned to be completed in September 2021, followed by the manufacturing equipment and process utilities to be installed by Q3/2021. Biomay and its staff will move to the new site at the end of this year. After commissioning and qualification, the company will start up manufacturing operations for its clients in Q1/2022.
About the Facility
A number of parallel GMP manufacturing lines will be erected on a total floor area of about 4000 square meters, increasing Biomay’s capacities by a factor of 10 with respect to batch size and volume (gross bioreactor scales: 5L, 50L, 150L and 750L). Furthermore, a dedicated area of the building will allow the production of innovative, personalized (patient-specific) batches.
About Biomay
Biomay AG is a biopharmaceutical contract development and manufacturing organization (CDMO) with international reach. In particular, Biomay is recognized as supplier for plasmid DNA (pDNA), recombinant proteins and messenger RNA (mRNA). Biomay’s clients include start-ups, midsize biotech companies and multinational enterprises, predominantly from Europe and the US. Beside manufacturing of active ingredients and drug products according to GMP standards, the company offers process and assay development as well as manufacturing of microbial cell banks.
Contact:
Dr. Christian Gruber / media@biomay.com /
+43-7966296-100 / www.biomay.com
:
Bilder
Om news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Følg pressemeldinger fra news aktuell GmbH
Registrer deg med din e-postadresse under for å få de nyeste sakene fra news aktuell GmbH på e-post fortløpende. Du kan melde deg av når som helst.
Siste pressemeldinger fra news aktuell GmbH
Valle Venia presents new song by LPS feat. Lara: Where will it take me27.2.2026 10:15:00 CET | Press release
The song describes the challenge of trusting the flow, relying on oneself, following one's own values with confidence.
Vyoma awarded ESA data procurement contract for space-based data on small space debris24.2.2026 10:53:34 CET | Press release
(Munich, February 24th, 2026) Vyoma, a Munich-based company providing Space Domain Awareness (SDA) capabilities, has been selected as the winner of the ESA tender on ”Data Procurement for Space-Based Statistical Data on Small Space Debris Phase 1”, funded via ESA‘s Space Safety Programme (S2P). ESA’s Meteoroid And Space debris Terrestrial Environment Reference (MASTER) model provides a description of the space environment around Earth, supporting satellite designers, operators and others with risk assessments. Currently, there exists a significant temporal and spatial knowledge gap for observations of space debris with sizes smaller than the detection limit of ground-based sensors. Vyoma's Flamingo-1 satellite is ideally positioned to generate the image data ESA is seeking. Flying “in-situ” at an altitude of 510 km, Flamingo-1's instrument can monitor large volumes of space at once. This sensor detects objects at long and short distances and captures small and fast objects reliably, im
Medi-Globe Launches mAI Companion® — the World’s First Real Time AI Assistant for Pancreatic EUS, Co Developed with IHU Strasbourg —Now MDR CE Marked and Available for Clinical Use in Europe24.2.2026 10:00:00 CET | Press release
Rohrdorf (Achenmühle), Germany — February 24, 2026 — Medi-Globe today announced the launch of mAI Companion®, a real-time medical AI solution designed to assist physicians in detecting pancreatic lesions during endoscopic ultrasound (EUS) — addressing one of the deadliest and most difficult-to-detect cancers, where earlier identification can dramatically change patient outcomes.
Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect24.2.2026 08:43:52 CET | Press release
Aachen, Germany & Victoria, Australia, 24 February 2026 – Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique products, announced today that they have entered into a definitive agreement whereby Clinect will have the exclusive Australian rights to Qutenza®, a topical, non-systemic, non-opioid patch indicated for the management of peripheral neuropathic pain. Under the agreement, Clinect will be responsible for obtaining marketing authorisation for Qutenza® in Australia and, upon approval, marketing and distributing the product in Australia.
Clean energy needs a clean planet: PLAN-B NET ZERO and everwave launch joint initiative20.2.2026 13:26:02 CET | Press release
(Berlin, Germany) A strong start to 2026. PLAN-B NET ZERO enters into a partnership with the Aachen-based environmental scale-up everwave. With the guiding principle ‘1 euro = 1 kilogram of waste’, the partners recovered 10,000 kilograms of waste from rivers in Cambodia at the start of the initiative Around 11 million tonnes of plastic waste enter the oceans every year. Without effective countermeasures, this volume could almost triple by 2040. Studies show that about 80 percent of marine plastic reaches the sea via roughly 1,656 rivers worldwide. To date, everwave has removed more than 2.4 million kilograms of plastic from rivers in Cambodia, Albania, and Thailand. The company uses waste collection boats, barriers, and manual cleanups to stop plastic before it reaches the oceans. At the same time, mobile sorting and recycling solutions return materials efficiently to the circular economy. AI support optimizes collection routes to clean as many waterways as possible in a sustainable wa
I vårt presserom finner du alle våre siste pressemeldinger, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.
Besøk vårt presserom